Extended Endocrine Therapy for Premenopausal Women With Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

July 31, 2014

Study Completion Date

September 30, 2014

Conditions
Breast Cancer
Interventions
DRUG

leuprolide

Given intramuscularly beginning on day 1 and then either 7.5 mg every month or 22.5 mg every 3 months for two years

DRUG

letrozole

Taken orally once a day 6-8 weeks after initial leuprolide administration

DRUG

zoledronic acid

If desired, given intravenously every 6 months for a total of 4 injections (optional)

Trial Locations (4)

80217

University of Colorado, Denver

02115

Beth Israel Deaconess Medical Center, Boston

02215

Dana-Farber Cancer Institute, Boston

02462

Newton Wellesley Hospital, Newton

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Novartis

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER